Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Breast Cancer treatment details. Chemotherapy. Memorial Sloan-Kettering Cancer Center, New York, NY, United States

Survival: 11.4 months
Toxicity Grade: 5
Treatments: Chemotherapy
Country: United States
City/State/Province: New York, NY
Hospital: Memorial Sloan-Kettering Cancer Center
Journal: Link
Date: 5/2013

This phase 2 study involved female HER2-negative advanced breast cancer patients previously treated with bevacizumab who were divided into two separate treatment groups patients. There were 81 patients in group A with an average age of 53.5 years. Group B had 79 patients with an average age of 54.2 years.

Patients in group A were treated with a chemotherapy agent (either gemcitabine or capecitabine) and the biologic therapy agent sorafenib, which is a multikinase inhibitor that interferes with cancer cell growth.

Patients in group B were treated with gemcitabine or capecitabine and a placebo.

Treatment-related deaths due to heart attack and brain hemorrhage were reported for group A. Grade 4 neutropenia and thrombocytopenia, and grade 3 fatigue, hand-foot skin reaction, and inflammation of the stomach lining were also reported.

One treatment-related death due to liver failure was reported for group B. Grade 4 neutropenia was also reported.

The median overall survival for groups A and B was 13.4 and 11.4 months, respectively.

This study was partially supported by Onyx Pharmaceuticals and Bayer Healthcare Pharmaceuticals.

Correspondence: Dr. Clifford A. Hudis; email:

E-mail to a Friend Email Physician More Information